{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:46:24Z","timestamp":1760402784255,"version":"build-2065373602"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Given the continued emergence of SARS-CoV-2 variants of concern as well as unprecedented vaccine development, it is crucial to understand the effect of updated vaccine formulations at the population level. While bivalent formulations developed during 2022 have had higher efficacy in vaccine trials, translating these findings to real-world effectiveness is challenging due to diversity in immune history, especially in settings with a high degree of natural immunity. Known socioeconomic disparities in key metrics such as vaccine coverage, social distancing, and access to healthcare have likely shaped the development and distribution of this immune landscape. Yet little has been done to investigate the impact of booster formulation in the context of host heterogeneity. Here, we present work undertaken in 2022-2023 to inform the World Health Organization\u2019s Immunization and Vaccines Related Implementation Research Advisory Committee (IVIR-AC), at a time when policymakers were considering optimal boosting strategies. Using two complementary mathematical models that capture host demographics and immune histories over time, we investigated the potential impacts of bivalent and monovalent boosters, inspired by disease dynamics in low- and middle-income countries (LMICs). These models allowed us to test the role of natural immunity and cross-protection in determining optimal booster strategy. Our results show that in hypothetical populations with high pre-existing immunity in the 2022-23 season, disease-related deaths from a new variant would be more sensitive to boosting\/no boosting than booster formulation (bivalent vs. monovalent) - and if using bivalent formulations would result in delayed implementation compared to monovalent, it would almost always be better to implement monovalent immediately. However, deaths might be more sensitive to bivalent formulations in populations with low pre-existing immunity. These findings suggest that for many places where acquiring new vaccine stock may be economically prohibitive, monovalent boosters could still have been implemented where pre-existing immunity was high. While this analysis focuses on policy concerns in 2022, these results remain relevant now amidst ongoing questions about optimal booster formulation and timing to combat emerging transmission waves of COVID-19.<\/jats:p>","DOI":"10.1038\/s41598-025-19659-3","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:59:33Z","timestamp":1760363973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of immune history when choosing a SARS-CoV-2 booster strategy"],"prefix":"10.1038","volume":"15","author":[{"given":"Soren L.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iffat","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haylee","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela P.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia N. M.","family":"Kraay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"19659_CR1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41564-022-01105-z","volume":"7","author":"R Ke","year":"2022","unstructured":"Ke, R. et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat. Microbiol. 7, 640\u2013652 (2022).","journal-title":"Nat. Microbiol."},{"key":"19659_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature04153","volume":"438","author":"JO Lloyd-Smith","year":"2005","unstructured":"Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the effect of individual variation on disease emergence. Nature 438, 355\u2013359 (2005).","journal-title":"Nature"},{"key":"19659_CR3","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthplace.2021.102694","volume":"72","author":"J Huang","year":"2021","unstructured":"Huang, J., Kwan, M.-P. & Kan, Z. The superspreading places of COVID-19 and the associated built-environment and socio-demographic features: A study using a spatial network framework and individual-level activity data. Health Place 72, 102694 (2021).","journal-title":"Health Place"},{"key":"19659_CR4","doi-asserted-by":"crossref","first-page":"eabg5298","DOI":"10.1126\/science.abg5298","volume":"372","author":"GE Mena","year":"2021","unstructured":"Mena, G. E. et al. Socioeconomic status determines COVID-19 incidence and related mortality in Santiago, Chile. Science 372, eabg5298 (2021).","journal-title":"Science"},{"key":"19659_CR5","doi-asserted-by":"crossref","first-page":"eadh9920","DOI":"10.1126\/sciadv.adh9920","volume":"9","author":"SL Larsen","year":"2023","unstructured":"Larsen, S. L. et al. Quantifying the impact of SARS-CoV-2 temporal vaccination trends and disparities on disease control. Sci. Adv. 9, eadh9920 (2023).","journal-title":"Sci. Adv."},{"key":"19659_CR6","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S2468-2667(21)00160-2","volume":"6","author":"J Riou","year":"2021","unstructured":"Riou, J. et al. Socioeconomic position and the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. Lancet Public Health 6, e683\u2013e691 (2021).","journal-title":"Lancet Public Health"},{"key":"19659_CR7","volume":"5","author":"ZJ Madewell","year":"2022","unstructured":"Madewell, Z. J., Yang, Y., Longini, I. M., Halloran, M. E. & Dean, N. E. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. JAMA Netw. Open 5, e229317 (2022).","journal-title":"JAMA Netw. Open"},{"key":"19659_CR8","unstructured":"Coronavirus (covid-19) update: Fda authorizes moderna, pfizer-biontech bivalent covid-19 vaccines for use as a booster dose. https:\/\/web.archive.org\/web\/20220901035343\/, https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use?utm_medium=email&utm_source=govdelivery (2022)."},{"key":"19659_CR9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41577-022-00771-8","volume":"22","author":"R Suryawanshi","year":"2022","unstructured":"Suryawanshi, R. & Ott, M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining?. Nat. Rev. Immunol. 22, 591\u2013592 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"19659_CR10","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/s41564-022-01246-1","volume":"7","author":"CW Tan","year":"2022","unstructured":"Tan, C. W. et al. SARS-CoV-2omicron variant emerged under immune selection. Nat. Microbiol. 7, 1756\u20131761 (2022).","journal-title":"Nat. Microbiol."},{"key":"19659_CR11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"K R\u00f6ltgen","year":"2022","unstructured":"R\u00f6ltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025\u20131040 (2022).","journal-title":"Cell"},{"key":"19659_CR12","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.it.2021.09.001","volume":"42","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol. 42, 956\u2013959 (2021).","journal-title":"Trends Immunol."},{"key":"19659_CR13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1126\/science.aag1322","volume":"354","author":"KM Gostic","year":"2016","unstructured":"Gostic, K. M., Ambrose, M., Worobey, M. & Lloyd-Smith, J. O. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354, 722\u2013726 (2016).","journal-title":"Science"},{"key":"19659_CR14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.tim.2021.05.009","volume":"29","author":"RJ Oidtman","year":"2021","unstructured":"Oidtman, R. J. et al. Influenza immune escape under heterogeneous host immune histories. Trends Microbiol. 29, 1072\u20131082 (2021).","journal-title":"Trends Microbiol."},{"key":"19659_CR15","doi-asserted-by":"crossref","unstructured":"Zelner, J., Naraharisetti, R. & Zelner, S. Invited commentary: to make long-term gains against infection inequity, infectious disease epidemiology needs to develop a more sociological imagination. Am. J. Epidemiol. kwad044 (2023).","DOI":"10.1093\/aje\/kwad044"},{"key":"19659_CR16","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1038\/s41467-022-30688-8","volume":"13","author":"M Tizzoni","year":"2022","unstructured":"Tizzoni, M. et al. Addressing the socioeconomic divide in computational modeling for infectious diseases. Nat. Commun. 13, 2897 (2022).","journal-title":"Nat. Commun."},{"key":"19659_CR17","doi-asserted-by":"crossref","first-page":"aaa4339","DOI":"10.1126\/science.aaa4339","volume":"347","author":"H Heesterbeek","year":"2015","unstructured":"Heesterbeek, H. et al. Modeling infectious disease dynamics in the complex landscape of global health. Science 347, aaa4339 (2015).","journal-title":"Science"},{"key":"19659_CR18","unstructured":"CDC. Monitoring variant proportions. https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions."},{"key":"19659_CR19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/infdis\/jiac332","volume":"227","author":"M Manali","year":"2023","unstructured":"Manali, M. et al. SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity. J. Infect. Dis. 227, 40\u201349 (2023).","journal-title":"J. Infect. Dis."},{"key":"19659_CR20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-022-04865-0","volume":"607","author":"RK Suryawanshi","year":"2022","unstructured":"Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 omicron without vaccination. Nature 607, 351\u2013355 (2022).","journal-title":"Nature"},{"key":"19659_CR21","unstructured":"Who coronavirus (COVID-19) dashboard. https:\/\/covid19.who.int\/ (2022)."},{"key":"19659_CR22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2215471","volume":"388","author":"D-Y Lin","year":"2023","unstructured":"Lin, D.-Y. et al. Effectiveness of bivalent boosters against severe omicron infection. N. Engl. J. Med. 388, 764\u2013766 (2023).","journal-title":"N. Engl. J. Med."},{"key":"19659_CR23","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S1473-3099(23)00374-2","volume":"23","author":"A Mateo-Urdiales","year":"2023","unstructured":"Mateo-Urdiales, A. et al. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA. 5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study. Lancet. Infect. Dis 23, 1349\u20131359 (2023).","journal-title":"Lancet. Infect. Dis"},{"key":"19659_CR24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMp2215780","volume":"388","author":"PA Offit","year":"2023","unstructured":"Offit, P. A. Bivalent COVID-19 vaccines\u2014a cautionary tale. N. Engl. J. Med. 388, 481\u2013483 (2023).","journal-title":"N. Engl. J. Med."},{"key":"19659_CR25","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"19659_CR26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.chom.2023.12.003","volume":"32","author":"R Nesamari","year":"2024","unstructured":"Nesamari, R. et al. Post-pandemic memory t cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated ba. 2.86 variant. Cell Host Microbe 32, 162\u2013169 (2024).","journal-title":"Cell Host Microbe"},{"key":"19659_CR27","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2666-5247(23)00255-0","volume":"5","author":"L Guo","year":"2024","unstructured":"Guo, L. et al. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: A longitudinal cohort study. Lancet Microbe 5, e24\u2013e33 (2024).","journal-title":"Lancet Microbe"},{"key":"19659_CR28","doi-asserted-by":"crossref","first-page":"e2213606","DOI":"10.1001\/jamanetworkopen.2022.13606","volume":"5","author":"J Jung","year":"2022","unstructured":"Jung, J. et al. Transmission and infectious SARS-CoV-2 shedding kinetics in vaccinated and unvaccinated individuals. JAMA Netw. Open 5, e2213606\u2013e2213606 (2022).","journal-title":"JAMA Netw. Open"},{"key":"19659_CR29","doi-asserted-by":"crossref","unstructured":"Burki, T. K. Omicron variant and booster COVID-19 vaccines. Lancet Respir. Med. 10 (2022).","DOI":"10.1016\/S2213-2600(21)00559-2"},{"key":"19659_CR30","doi-asserted-by":"crossref","first-page":"e2255978","DOI":"10.1001\/jamanetworkopen.2022.55978","volume":"6","author":"J Briggs","year":"2023","unstructured":"Briggs, J. et al. Seroprevalence of antibodies to SARS-CoV-2 in rural households in eastern Uganda, 2020\u20132022. JAMA Netw. Open 6, e2255978\u2013e2255978 (2023).","journal-title":"JAMA Netw. Open"},{"key":"19659_CR31","unstructured":"CDC. 2022-2023 nationwide COVID-19 infection- and vaccination-induced antibody seroprevalence (blood donations). https:\/\/covid.cdc.gov\/covid-data-tracker\/#nationwide-blood-donor-seroprevalence-2022."},{"key":"19659_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004107","volume":"19","author":"I Bergeri","year":"2022","unstructured":"Bergeri, I. et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med. 19, e1004107 (2022).","journal-title":"PLoS Med."},{"key":"19659_CR33","unstructured":"CDC. Cdc recommends updated 2024-2025 COVID-19 and flu vaccines for fall\/winter virus season. https:\/\/www.cdc.gov\/media\/releases\/2024\/s-t0627-vaccine-recommendations.html."},{"key":"19659_CR34","unstructured":"Van, V. A new evolutionary law. (1973)."},{"key":"19659_CR35","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/s41564-023-01504-w","volume":"8","author":"C Roemer","year":"2023","unstructured":"Roemer, C. et al. SARS-CoV-2 evolution in the omicron era. Nat. Microbiol. 8, 1952\u20131959 (2023).","journal-title":"Nat. Microbiol."},{"key":"19659_CR36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41423-023-01116-8","volume":"21","author":"S Cankat","year":"2023","unstructured":"Cankat, S., Demael, M. & Swadling, L. In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Cell. Mol. Immunol. 21, 103\u2013118 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"19659_CR37","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.chom.2023.05.017","volume":"31","author":"CW Tan","year":"2023","unstructured":"Tan, C. W., Valkenburg, S. A., Poon, L. L. & Wang, L.-F. Broad-spectrum pan-genus and pan-family virus vaccines. Cell Host Microbe 31, 902\u2013916 (2023).","journal-title":"Cell Host Microbe"},{"key":"19659_CR38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3201\/eid2902.221422","volume":"29","author":"DS Khoury","year":"2023","unstructured":"Khoury, D. S. et al. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection. Emerg. Infect. Dis. 29, 381 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"19659_CR39","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/vaccines10091548","volume":"10","author":"C Dimeglio","year":"2022","unstructured":"Dimeglio, C. et al. Antibody titers and protection against omicron (ba. 1 and ba. 2) SARS-CoV-2 infection. Vaccines 10, 1548 (2022).","journal-title":"Vaccines"},{"key":"19659_CR40","unstructured":"Mathieu, E. et al. Coronavirus pandemic (COVID-19). Our World in Data (2020). https:\/\/ourworldindata.org\/coronavirus."},{"key":"19659_CR41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004195","volume":"20","author":"AB Hogan","year":"2023","unstructured":"Hogan, A. B. et al. Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study. PLoS Med. 20, e1004195 (2023).","journal-title":"PLoS Med."},{"key":"19659_CR42","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1038\/s41467-023-39736-3","volume":"14","author":"AB Hogan","year":"2023","unstructured":"Hogan, A. B. et al. Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach. Nat. Commun. 14, 4325 (2023).","journal-title":"Nat. Commun."},{"key":"19659_CR43","unstructured":"Population estimates and projections for 227 countries and areas. https:\/\/www.census.gov\/data-tools\/demo\/idb\/#\/pop?COUNTRY_YEAR=2022&COUNTRY_YR_ANIM=2022&FIPS_SINGLE=EC&FIPS=EC&popPages=BYAGE&POP_YEARS=2022&menu=popViz (2022)."},{"key":"19659_CR44","volume":"123","author":"Y Cao","year":"2005","unstructured":"Cao, Y., Gillespie, D. T. & Petzold, L. R. Avoiding negative populations in explicit Poisson tau-leaping. J. Chem. Phys. 123, 054104 (2005).","journal-title":"J. Chem. Phys."},{"key":"19659_CR45","unstructured":"Harrell Jr, F. E. Hmisc: Harrell Miscellaneous. https:\/\/github.com\/harrelfe\/hmisc. R package version 5.2-0 (2024)."},{"key":"19659_CR46","doi-asserted-by":"crossref","unstructured":"Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. (2023).","DOI":"10.1016\/S1473-3099(22)00801-5"},{"key":"19659_CR47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005697","volume":"13","author":"K Prem","year":"2017","unstructured":"Prem, K., Cook, A. R. & Jit, M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput. Biol. 13, e1005697 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"19659_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-021-10561-x","volume":"21","author":"M Yechezkel","year":"2021","unstructured":"Yechezkel, M. et al. Human mobility and poverty as key drivers of COVID-19 transmission and control. BMC Public Health 21, 1\u201313 (2021).","journal-title":"BMC Public Health"},{"key":"19659_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-00416-1","volume":"11","author":"E Bok\u00e1nyi","year":"2021","unstructured":"Bok\u00e1nyi, E., Juh\u00e1sz, S., Karsai, M. & Lengyel, B. Universal patterns of long-distance commuting and social assortativity in cities. Sci. Rep. 11, 1\u201310 (2021).","journal-title":"Sci. Rep."},{"key":"19659_CR50","unstructured":"Covid-19 advice for the public: Getting vaccinated. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice (2023)."},{"key":"19659_CR51","doi-asserted-by":"crossref","first-page":"20220477","DOI":"10.1098\/rsif.2022.0477","volume":"19","author":"ANM Kraay","year":"2022","unstructured":"Kraay, A. N. M. et al. The role of booster vaccination and ongoing viral evolution in seasonal circulation of sars-cov-2. J. R. Soc. Interface 19, 20220477 (2022).","journal-title":"J. R. Soc. Interface"},{"key":"19659_CR52","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the omicron (b.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"19659_CR53","unstructured":"Zeneca, A. Covid-19 vaccine astrazeneca real-world evidence summary. https:\/\/www.astrazeneca.com\/content\/dam\/az\/covid-19\/media\/factsheets\/COVID-19_Vaccine_AstraZeneca_Real-World_Evidence_Summary.pdf (2021)."},{"key":"19659_CR54","unstructured":"Zeneca, A. Boosting with astrazeneca\u2018s vaccine provides high protection against omicron, equivalent to mrna covid-19 vaccines. https:\/\/www.astrazeneca.com\/country-sites\/thailand\/press-releases\/boosting-with-astrazenecas-vaccine-provides-high-protection-against-omicron-equivalent-to-mrna-covid-19-vaccines.html (2022)."},{"key":"19659_CR55","first-page":"1","volume":"22","author":"R Solante","year":"2022","unstructured":"Solante, R. et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness & safety during the omicron-dominant phase of the pandemic. Research Square 22, 1\u201316 (2022).","journal-title":"Research Square"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19659-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19659-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:00:01Z","timestamp":1760364001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19659-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19659"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19659-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"35640"}}